Patients with primary hypercholesterolemia treated up to 12 months with anti-PCSK9 mAbs not only decreased their LDL-C concentration by at least 50–60% but also showed a significant reduction of platelet activation accompanied by the improvement of platelet sensitivity to the inhibitory effects of aspirin [15]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.